Life Sciences Archive » May, 2026

Life Sciences - May, 2026

271 articles

• Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now
• Justices Told USPTO's 'Settled Expectations' Rule Flouts Law
• Ohio AG Says Cigna Can't Use Sherman Act To Ax State Case
• Teva Ruling Offers Patentees New Support For Genus Claims
• Consulting Co. Says Ex-Owner Failed To Fulfill Sales Duties
• Blood Test Lab Owner Gets 4 Years For $11M Tax Evasion
• Full 4th Circ. To Rethink W.Va., Md. 340B Drug Discount Laws
• DOJ Final Rule On Medical Pot Comes Under New Challenge
• Taxation With Representation: Latham, White & Case, Vischer
• Your Next Litigation Hold Should Cover AI Chat Logs
• UnitedHealthcare Defrauded Mass. Of $100M, AG Says
• Calif. AG Sues 23andMe Over Lapses In Genetic Data Security
• WHO 'Changed The Rule' To Find Talc-Cancer Link, Jury Told
• Trans Patients Say Stanford Can't Give DOJ Medical Records
• Injury Law Roundup: Freight Brokers, Uber Lose Key Cases
• Hospital Operator, Execs Ink $32M FCA Settlement With Feds
• McDermott-Led Ampersand Clinches $1.5B Fund
• 3 Federal Circuit Clashes To Watch In June
• Zoetis Hit With Investor Suit Over Slowed Pet Drug Sales
• J&J Unit Cleared In Blood Pump Patent Suit In Mass.
• Chancery Tosses Insider Financing Suit Against Ayala Brass
• Abbott Labs Settles Ill. Genetic Privacy Suit
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• High Court's Abortion Pill Stay Reinforces Appellate Principles
• Cannabis Policy Shift May Reshape Banking, Insolvency Risks
• International Patent Licensing System Must Be Maintained
• Husch Blackwell Adds Manatt Healthcare Duo In LA
• Ex-Reebok CEO Says Biotech Investor Suit Was Shakedown
• 9th Circ. Won't Revisit FCA Ruling Over Drug Price Program
• Split Fed. Circ. Says $452M Trade Secret Case Was Untimely
• Studying Foreign Languages Makes Me A Better Lawyer
• Pharmacies Beat Fla. Hospitals' Opioids Suit
• Inovio Brass Hit With Suit Over FDA Approval Claims
• 3 Generic Drug Antitrust Deals Totaling $17.9M Get Final Nod
• ProPublica Denied Access To Ranbaxy Antitrust MDL Docs
• Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row
• NJ Justices Revive Eye Injury Suit For 'Gatekeeping' Test
• 10 US Patent Pressure Points For EU Life Sciences Cos.
• Stock Trade Co. Wants Out Of Mallinckrodt Clawback Suit
• Squires Institutes 3 IPRs, Refuses Case With Limited Impact
• Squires Says Sun PGR Petition Denied For Not Naming Parent
• Pierce Atwood Rips Billionaire's 'Absurd' Suit Over Asset Sale
• Catching Up With Delaware's Chancery Court
• 9th Circ. Backs Reinstating DEI Grants Nixed By Trump
• Conn. Drug Price Law Still Allows Hikes, 2nd Circ. Told
• Beasley Allen Fails To Overturn J&J Talc Disqualification
• Squires' Institution Flips Are Increasing Uncertainty At PTAB
• Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B
• Law360 Reveals Titans Of The Plaintiffs Bar
• J&J 's 'Pure' Baby Powder Ads Were Pure Lies, Jury Told
• Health Workers Say US Solicitor Wrong In NY Vax Case
• Healthcare Orgs Push DC Court To Block Student Loan Caps
• Opioid Plaintiffs Want Sanctions Over McKinsey Deletions
• Don't Miss It: Cooley, Simpson Thacher Steer Hot Deals
• Sizing Up The Rescheduling Hurdles Medical Pot Cos. Face
• Consumer Drops TCPA Suit Against Colo. Supplement Co.
• Trump's Melding Of Politics, Antitrust Hard To Roll Back
• PBM Swaps Cravath For WilmerHale In Price-Fixing Suit
• J&J Used Ellipsis To Nix Asbestos In Report To FDA, Jury Told
• 9th Circ. Says Judge Overstepped In Fluoride Risk Case
• NFL Teams Valued At $9B In Stake Sales, And Other Rumors
• Insurer Can't Nix Counterclaims In $1.8M Judgment Dispute
• UCB Staves Off Seizure Drug Competition After Bench Trial
• 9th Circ. Told To Reject J&J Unit's $442M Antitrust Appeal
• Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• BigLaw Deals Scandal Puts Boston Back On White Collar Map
• Immunity Bid Can't Stop Discovery In THC Abuse Registry Suit
• Amgen Wants To Preserve Right To Seek Double Tax Relief
• Texas Comptroller Tells 5th Circ. To Toss E-Cig Ban Suit
• Fed. Circ. Backs Lupin Win In Generic Kidney Drug Case
• AmeriHealth Unit, PBM Sued Over Prescription Claim Fees
• Zantac Cases To Proceed During Appeal Of Recusal Denial
• NY Times Word Puzzles Make Me A Better Lawyer
• Prof. Hired By J&J In 1970s Found Asbestos In Talc, Jury Told
• DOJ, Drugmakers Spar After Justices Snub 6 Negotiation Suits
• Minnesota Jury Awards $10.2M In Talc Mesothelioma Trial
• 2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award
• 1st Circ. Allows Transfer Of RI Youth Care Info To Texas Court
• Refusing Sandoz Parent Dismissal 'Clear Error,' Court Told
• Eli Lilly Loses Bid To Limit Ex-FDA Chief's Take In GLP-1 MDL
• Tiversa Escapes LabMD's Final Defamation Claims
• Engaging With FDA's New Complete Response Letter Policy
• Eli Lilly Paying Up To $202M In Genetic Medicine Deal
• Intellia Drops Counterclaims In Gene-Editing Patent Case
• Squires Institutes 5 Patent Reviews, Rejects 7 Others
• FTC 'Close' To Final PBM Insulin Price Deal With OptumRx
• Law School's Missed Lesson: Diagnose Before Arguing
• Quinn Emanuel Owes More Sanctions In Guardant Fight
• Monsanto To Pay Mich., RI Up To $302M Over PCB Pollution
• Toxicologist Denies J&J Wanted To 'Control' Talc Study
• Calif. Urges 9th Circ. To Revive Pay-For-Delay Restrictions
• Apple's Fed. Circ. Review Bid Gets Support In Watch Ban Feud
• PTAB Ends Repetitive Challenges To Mercury Removal IP
• Fed. Circ. Rehearing Sought In $18M Penile Implant Dispute
• Trump's Psychedelics EO Creates A Regulatory Collision
• A Fed. Circ. Blueprint For Drafting Medical Device Patents
• Mentari, InMed Merge In Deal Backed By $290M Funding
• DTSA Data Shows Hidden Value Of Ex Parte Seizure Filings
• Novo Nordisk Says Investor Suit Pleadings Are Impermissible
• Becoming The Biz-Savvy GC That Portfolio Companies Need
• Fed. Circ. Restores 2 Patent Suits On Same Standing Issue
• Feds Say High Court Should Skip Religious Bias Vax Fight
• AI Regulatory Gaps May Fuel FCA Enforcement Action
• Comic Gets Serious About Mom's Cancer At J&J Talc Trial
• Squires, Stewart Zero In On PTAB's Burden Of Proof At Panel
• Woman Says Spinal Device Caused Permanent Nerve Damage
• Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit
• Chancery Sends Sinovac Biotech Suit To Antigua And Barbuda
• PBMs Tell Mich. Court They're Not To Blame For Opioid Abuse
• Aetna Denied A Freeze On Trans Facial Surgery Order
• Takeda Liable In IBS Drug Pay-For-Delay Trial
• Catching Up With Delaware's Chancery Court
• Justices Deny Eli Lilly's Qui Tam Constitutional Challenge
• High Court Spurns Pharma Challenges To IRA Drug Price Talks
• Judges On AI: How Courts Can Survive The Tech Revolution
• 'Skinny Label' Arguments Spotlight Induced Infringement Risk
• Fed. Circ. Drops A Theme Song, Talks Guest Judges
• Med Device Groups 'Overshot' In Fair Use Args, Judge Says
• Pharmacies Stuck With CVS Arbitration Mandate At 9th Circ.
• Edwards Investors Sue In Chancery Over $16.4B Stock Drop
• Texas Hospital Creates 'De-Transition Clinic' After Settlement
• 4th Circ. Hands Express Scripts Jury Trial In W.Va. Opioid Suit
• Insurer Owes No Coverage In Ill. Genetic Testing Fraud Suit
• $19.2M Joint Juice Deal Ends Calif. False Ad Suit
• Marketer Says It Was Pawn In Med Supplier's Crypto Pivot
• Startup Founder Disputes Increasingly Turn On Governance
• 3 AI Adoption Mistakes GCs Should Avoid
• Squires Lays Out Principles For Patent Review Discretion
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• NC Republicans Want Fetal Personhood Question On '26 Ballot
• Takeda To Pay $13.6M Over Antidepressant Drug Kickbacks
• Human Reproduction Proves Talc Can Reach Ovaries, Jury Told
• Squires Walks Back 5 More IPR Grants Over Inconsistent Args
• House Passes Bill To Narrow Biofuel Blending Exemption
• Med Device Co.'s CEO Touted Growth, Netted $39M, Suit Says
• Albertsons Not Covered In Opioid Litigation, Del. Judge Says
• Insider Trading Case Shows BigLaw Associate Vetting Gaps
• Fortive, Subsidiary Seek Early Win In Wrongful Firing Suit
• High Court Maintains Abortion Pill Access Amid Circuit Appeal
• Takeda Cashed In From Delay Of Generic IBS Drug, Jury Told
• BeiGene Must Face AbbVie's Chemical Trade Secret Claims
• Playing Basketball Makes Me A Better Lawyer
• Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout
• Ga. Panel Quiet On Fate Of $20M Bard Cancer Verdict
• EPA Listing Signals New Scrutiny Of Drugs In Drinking Water
• Time For Trial, Judge Says, Nixing DQ Appeal In Generics MDL
• How Del. Courts Will Likely Evaluate AI Oversight Claims
• Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug
• 'Powerful' Risk For Women Using Talc, UC Prof Tells Jury
• 3 NJ Employers Accused Of Pregnancy Discrimination
• Walgreens Investors' Opioid Suit Is Time-Barred, Judge Says
• Pa. Jury Finds Dispensary Subjected Fired Manager To Bias
• Bayer, Buyers Get Final OK Of $4.85M Benzene Settlement
• 5th Circ.'s Abortion Pill Order Is Shaky On Multiple Grounds
• Becton Hernia Mesh Antitrust Case Survives Dismissal
• The Biz Court Digest: Georgia Court Has Business On Its Mind
• Conn. Doctor Asked To Pay $880K In IVF Fraud Dispute
• Crowell & Moring Opens Minneapolis Office With 8 Lawyers
• DC Circ. Asked To Review EPA Incinerator Standards
• NJ Court Not Sure Bristol-Myers Investor Pled Negligence
• Attys For Tufts Profs Didn't Blink In A Tenure Standoff
• AliveCor Wants Apple Health Monitor Patent Claims Tossed
• Elanco On Hook For Bulk Of $9M Flea & Tick Meds Deal
• USPTO Must Address The Right Question In Sanofi Case
• Commerce Details Path To Discount For 100% Pharma Tariff
• 4 Emerging Approaches To AI Protective Order Language
• Pa. Panel Struggles With Oversight Of $2.2B Opioid Fund
• Makary Out As FDA Commissioner, Trump Says
• SPAC, Investors Sue Aesthetics Co. Over Failed $250M Merger
• FDA Leaders Outline How AI Is Shaping The Agency's Work
• Celgene Gets Final OK For $239M Deal, Atty Fees
• Female Medtronic Manager's Firing Driven By Bias, Court Told
• NJ Justices Back Coverage Exclusion Reservation Of Rights
• Wash. Says Novartis Isn't Harmed By 340B Drug Pricing Law
• Nestlé Sues To Unmask Amazon Sellers Of 'Stolen' Vitamins
• Mead Johnson Heads To Trial In Ill. Baby Formula MDL
• Beauty Tech Co. Execs Beat Investor Suit For Good
• Pharma CEO's Role In Ex-Exec's Contract Permits Deposition
• What Justices Are Focusing On In 'Skinny Label' Patent Case
• Amgen Late To Raise Double-Taxation Claim, Tax Court Told
• Trading Scheme Is A 'Wake-Up Call' For BigLaw Compliance
• Justices Extend Stay On 5th Circ. Mifepristone Decision
• Accelerated Psychedelic Therapy Pathways Require Caution
• Fed. Circ. Backs Atty Fee Ruling In Bone Fusion Patent Row
• Plaintiffs' Attys Sanctioned In Tylenol MDL, Sparking Appeal
• Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved
• Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition
• FTC's Gender-Care Probe Likely Retaliatory, Judge Says
• 10x, Curio Settle Genomics Patent Suit Before Trial
• Sports Tech Co. Says Judge Made Own Patent Eligibility Case
• 10x, Harvard Sue Sequencing Co. Over Biology Patents
• Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades
• Covington, Cooley Lead Drugmaker Odyssey's $279M IPO
• Squires Says Yes To 7 Patent Petitions, No To A Dozen More
• How 10 Years Of Case Law Have Shaped The DTSA
• Don't Miss It: Paul Hastings, V&E Steer Latest Hot Deals
• The Ethics And Practicalities Of Representing AI Agents
• Catalent Agrees To Pay $78M To Settle Securities Suit
• Walgreens Loses Atty Sanctions Bid In Georgia Bias Suit
• Cardiac Device Co. Says Ex-Manager Took Secrets To Rival
• Squires Says Fitness Tracker Patent Date Key To PGR Ruling
• Fed. Circ. Judges Stuck On Drug Efficacy's Role In Patents
• J&J Feared FDA's 'Disturbing Proposal' To Test Talc, Jury Told
• La. Says Mailed Abortion Pills Harm State Budget, Sovereignty
• Judge, In 'Difficult Position,' OKs Rare Patent Defense
• $495M Win Upheld In Abbott Baby Formula Bellwether Trial
• Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill
• Bayer Loses Bid To Undo Class In 'One A Day' Label Suit
• Liberty Left Client Info Vulnerable To Hackers, Suit Alleges
• Judge Knocks Out Pfizer Partner's Vax Case Against GSK
• Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud
• AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit
• Ex‑Novartis Atty Wins Revival Of Whistleblower Claims
• Davis Polk-Led Roche To Pay Up To $1.05B For PathAI
• King & Spalding Adds Congressional Health Policy Duo In DC
• Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs
• Toss Of Ex-Shkreli Atty's Deal May Be Error, 2nd Circ. Hints
• FBI Assistant GC Joins FBI Alum At Fenwick
• Speed Jigsaw Puzzling Makes Me A Better Lawyer
• Corcept Must Face Most Teva Mifepristone Antitrust Claims
• J&J, Tolmar Settle Patent Case Over Antipsychotic Drug
• 'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told
• Trulieve Twists Patent Pleading Standard, Cannabis Co. Says
• Judge Questions OMB Justification For Voiding Grants
• Judge Won't Certify Minn. Fraud Question In Cancer Drug MDL
• Calif. Justices Seem Divided On Gilead HIV Negligence Claim
• 9th Circ. Won't Revive Hospital Workers' Vaccine Bias Suit
• Alto Says Investors Use Hindsight In Suit Over Drug Trial
• CellCentric Closes Latest Funding Round With $220M In Tow
• DC Circ. Judge Jabs Pharma Atty For 10 Minutes In Price Fight
• Ex-FDA Chief Testifies 100s Of J&J Docs Tie Asbestos To Talc
• Cannabis Giants Sued Over Mental Health Marketing
• Sanofi Unit Gets Backup In Fed. Circ. Double Patenting Appeal
• ERISA Recap: 5 Litigation Developments From April
• Apple Urges Full Fed. Circ. To Undo Original Watch Import Ban
• $100M AI Investment Suit Must Be Arbitrated, Financier Says
• Mylan Strikes $4.5M Deal With Maryland Over EpiPen Pricing
• 4th Circ. Backs Raytheon In Ex-Workers' Vaccine Bias Case
• Amylyx Investors To Get $6.5M In ALS Drug Settlement
• CooperSurgical Strikes Deal To End Embryo Loss Class Suit
• Congress Should Ax Privacy Bill For Not Shielding Consumers
• Sandoz, Novartis Must Face Generics Claims From GM, Others
• Deutsche, Pathward Want Fintech Blacklist Suit Tossed
• Travelers Unit Says No Coverage In Cannabis Explosion Suits
• 'They Knew It': J&J Accused Of Hiding Talc Risk At LA Trial
• Biotech Overhyping Obesity Drug Hurt Investors, Suit Says
• Judge Shuts Down Invalidity Theory In Abiomed IP Case
• Suit's Dismissal Would Not Settle Gold Card Visa's Legality
• 2 AI Snafus Show Why Attys Can't Outsource Judgment
• Supplement Co. Says False Labeling Plaintiff Never Saw Ads
• Supreme Court Halts Abortion Drug Telehealth Ruling
• Justices Won't Hear Anti-Vaxxer Medical Board Suit
• Pharma Aims Torpedo At FCA After Bombshell 9th Circ. Ruling
• Judge, Atty Get In Shouting Match At Fatal Overdose Trial
• Twist Bioscience Investors Seek $17M Stock Fraud Deal OK
• Amazon Accused Of Selling Kids Sunscreen With Lead
• Fla. Jury Hears Menthol Smoker Succumbed To Addiction
• Texas High Court Revives Delta-8 THC Restrictions
• Biotech IPOs Surge Ahead As 2 Listings Raise $557M
• 5th Circ. Pauses Mail-Order Access To Abortion Pills
• Pharma Co. Investor Sues Over Misleading Aurinia Deal
• Congress Must Repair USPTO's Inter Partes Review Process
• Biotech Firm Wants Do-Over After Consultant's $58M Verdict
• Previewing FDA Preapproval Access In Psychedelics EO
• Vietnam Tops USTR Priority IP Watch List In Latest Report
• How Paul Clement Does It All
• NY's Growing Enviro Reg Framework Will Transform Projects
• Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion
• How 'Spillover' Effects Can Skew AI Securities Class Actions
• Mylan Inks $11M Deal With NC Over EpiPen Pricing